Intra-Cellular Therapies, Inc.

BOVESPA:I2TC34 Stock Report

Market Cap: R$55.7b

Intra-Cellular Therapies Future Growth

Future criteria checks 6/6

Intra-Cellular Therapies is forecast to grow earnings and revenue by 69.2% and 32.9% per annum respectively. EPS is expected to grow by 68.8% per annum. Return on equity is forecast to be 37.3% in 3 years.

Key information

69.2%

Earnings growth rate

68.8%

EPS growth rate

Pharmaceuticals earnings growth19.6%
Revenue growth rate32.9%
Future return on equity37.3%
Analyst coverage

Good

Last updated25 Dec 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BOVESPA:I2TC34 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,42238941249212
12/31/202593630566514
12/31/2024676-72-69214
9/30/2024614-86-63-62N/A
6/30/2024565-84-61-61N/A
3/31/2024514-111-99-98N/A
12/31/2023464-140-124-124N/A
9/30/2023420-155-162-161N/A
6/30/2023366-184-190-189N/A
3/31/2023311-228-248-247N/A
12/31/2022250-256-271-270N/A
9/30/2022188-298-305-304N/A
6/30/2022138-321-331-330N/A
3/31/2022103-304-296-295N/A
12/31/202184-284-260-260N/A
9/30/202171-259-255-255N/A
6/30/202156-237-239-239N/A
3/31/202138-232-227-227N/A
12/31/202023-227-230-230N/A
9/30/202010-207-196-197N/A
6/30/20203-187-163-163N/A
3/31/20201-160-144-144N/A
12/31/20190-148-129-128N/A
9/30/2019N/A-148-123-122N/A
6/30/2019N/A-155-122-121N/A
3/31/2019N/A-154-127-127N/A
12/31/2018N/A-155-119-118N/A
9/30/20180-145-115-114N/A
6/30/20180-126N/A-100N/A
3/31/20180-106N/A-91N/A
12/31/20170-98N/A-80N/A
9/30/20170-95N/A-84N/A
6/30/20170-102N/A-99N/A
3/31/20170-116N/A-88N/A
12/31/20160-116N/A-91N/A
9/30/20160-118N/A-98N/A
6/30/20160-120N/A-89N/A
3/31/20160-110N/A-106N/A
12/31/20150-105N/A-102N/A
9/30/20150-91N/A-73N/A
6/30/20150-65N/A-57N/A
3/31/20150-48N/A-32N/A
12/31/20141-31N/A-23N/A
9/30/20141-24N/A-25N/A
6/30/20142-22N/A-26N/A
3/31/20142-26N/A-27N/A
12/31/20133-27N/A-23N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: I2TC34 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (10.4%).

Earnings vs Market: I2TC34 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: I2TC34 is expected to become profitable in the next 3 years.

Revenue vs Market: I2TC34's revenue (32.9% per year) is forecast to grow faster than the BR market (7.9% per year).

High Growth Revenue: I2TC34's revenue (32.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: I2TC34's Return on Equity is forecast to be high in 3 years time (37.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 13:31
End of Day Share Price 2024/12/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intra-Cellular Therapies, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Ishan MajumdarBaptista Research
Jason Matthew GerberryBofA Global Research